Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, nail changes, particularly pitting, were associated with moderate to severe cases of alopecia areata and a positive family history, highlighting potential genetic factors in the condition.

This review explores nail changes associated with alopecia areata, noting their prevalence and impact on appearance and function, but reports no new clinical findings; the authors call for larger controlled trials.

This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.

This study found that young patients with severe AA are more prone to nail abnormalities such as pitting and leukonychia, with koilonychia and red spots lunula in more severe cases.

In this study, nail involvement was observed in 42.8% of children with alopecia areata, yet often went unrecognized, indicating that clinical and dermoscopic evaluations can improve detection and provide important prognostic information.

This study observed that 78.3% of patients with alopecia areata exhibited nail changes detectable by dermoscopy, notably nail pitting, in contrast to 14.2% of healthy controls, with these changes significantly associated with disease severity, age, and duration.

In this study, researchers found that patients with alopecia areata who had nail involvement or a history of autoimmune disease showed significantly higher red cell distribution width levels.

This study found that alopecia areata patients with eosinophilia were more likely to have severe hair loss, atopia, and nail abnormalities compared to those without eosinophilia.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, primarily pitting, and this was significantly associated with longer disease duration but not disease severity.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, predominantly pitting, which was significantly linked to longer disease duration but not the severity of scalp hair loss.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, and while this was associated with longer disease duration, it did not correlate with the severity of scalp hair loss.

In this case report, a patient with alopecia areata-associated nail changes experienced normalization of nail appearance and texture after 11 months of treatment with baricitinib, suggesting that the drug may be an effective option for similar cases, although further research is needed.

In this case study, the coexistence of thymoma-associated myasthenia gravis, alopecia areata, and twenty-nail dystrophy in a patient is reported, suggesting thymoma may increase the risk of developing these conditions.

This case report describes a 6-year-old child with twenty nail dystrophy and alopecia areata of the scalp.

This case study discusses a patient with persistent 20-nail dystrophy following alopecia areata, suggesting that "20-nail dystrophy" describes a condition with multiple potential causes.

Hydroxychloroquine effectively treated twenty-nail dystrophy in a patient with alopecia areata.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

This case report documented a 74-year-old female with alopecic patches and other skin issues during talquetamab therapy for multiple myeloma, suggesting that the drug may cause skin-related adverse effects due to reactivity to GPRC5D-expressing structures.

This article reviews the diagnosis and management of alopecia areata but reports no new research findings.

This study found that patients with alopecia areata often presented with multilocular patches, common scalp involvement, and associated conditions like atopic dermatitis; the disease predominantly affected younger individuals.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

This study found that short vellus hair and yellow dots are common dermoscopic findings in alopecia areata, with variations indicating disease activity or remission.

This study describes the clinical profile of scalp alopecia areata among patients at a tertiary care hospital, finding it more common in males, particularly those aged 21-30, with sudden onset and often asymptomatic progression.

This study found that alopecia areata was more common in males, most frequently appeared on the scalp, and typically presented as patchy hair loss.

This study found that in children with alopecia areata, younger age of onset was associated with more severe hair loss and a longer duration of the disease.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.